July 16, 2025 06:50 AM EDT
Deals
R&D

De­bio­pharm li­cens­es Re­pare’s first-in-class can­cer drug for $10M up­front

Ayisha Sharma

News Reporter

De­bio­pharm is spend­ing $10 mil­lion in cash on a can­cer drug de­vel­oped by its part­ner Re­pare Ther­a­peu­tics.

De­bio­pharm will get glob­al rights to lun­re­sert­ib, a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

PureTech CEO leaves just one week af­ter long­time chair steps down

Prime Med­i­cine CSO de­parts, re­veals new fund­ing; FDA lifts par­tial hold on Kezar drug

Prasad again over­rode FDA vac­cine re­view­ers, this time on Mod­er­na’s Covid shot for young kids

Up­dat­ed: FDA pub­lish­es repos­i­to­ry of 200+ drug re­jec­tion let­ters, promis­ing more in the fu­ture

Jeanne Mar­raz­zo, NI­AID di­rec­tor placed on leave, on 'biggest threat­s' to HIV med­i­cine

As­traZeneca says amy­loi­do­sis drug fails Phase 3 tri­als, but claims po­ten­tial in undis­closed sub­group

A service from the Financial Times